Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tocilizumab biosimilar - Gedeon Richter/Mochida Pharmaceutical

Next Previous
Drug Profile

Tocilizumab biosimilar - Gedeon Richter/Mochida Pharmaceutical

Alternative Names: LusiNEX; RGB-19; Tuyory

Latest Information Update: 10 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mycenax Biotech
  • Developer Gedeon Richter; Mochida Pharmaceutical; Mycenax Biotech
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antivirals; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Rheumatoid arthritis
  • Discontinued Juvenile rheumatoid arthritis

Most Recent Events

  • 27 Mar 2025 Preregistration for Rheumatoid arthritis in European Union (IV)
  • 26 Mar 2025 Preregistration for Rheumatoid arthritis in Japan (IV)
  • 16 Oct 2024 Tocilizumab biosimilar is still in phase I trials in Rheumatoid-arthritis(In volunteers) in New Zealand, Australia (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top